Display options
Share it on

JAAD Case Rep. 2016 Mar 04;2(2):114-6. doi: 10.1016/j.jdcr.2016.01.004. eCollection 2016 Mar.

Treatment of melanoma in-transit metastases with combination intralesional interleukin-2, topical imiquimod, and tretinoin 0.1% cream.

JAAD case reports

Jonathan S Leventhal, Ian D Odell, Suguru Imaeda, Emanual Maverakis, Brett A King

Affiliations

  1. Yale University School of Medicine, Department of Dermatology, New Haven, Connecticut.
  2. Yale University School of Medicine, Department of Dermatology, New Haven, Connecticut; Department of Veterans Affairs, West Haven, Connecticut.
  3. University of California, Davis, California.

PMID: 27051847 PMCID: PMC4810288 DOI: 10.1016/j.jdcr.2016.01.004

[No abstract available.]

Keywords: IL-2, interleukin-2; imiquimod; immunotherapy; interleukin-2; medical dermatology; melanoma; oncology

References

  1. Immunotherapy. 2011 May;3(5):653-71 - PubMed
  2. J Immunol. 2005 Feb 1;174(3):1259-68 - PubMed
  3. J Am Acad Dermatol. 2015 Oct;73(4):645-54 - PubMed
  4. Cancer Immunol Immunother. 2011 Apr;60(4):487-93 - PubMed
  5. Arch Dermatol. 2012 May;148(5):592-6 - PubMed
  6. Br J Dermatol. 2007 Feb;156(2):337-45 - PubMed
  7. Melanoma Res. 2012 Feb;22(1):19-29 - PubMed
  8. Dermatol Surg. 2004 Feb;30(2 Pt 2):244-7 - PubMed

Publication Types